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Abstract
The peptidomimetic LTX109 (arginine-tertbutyl tryptophan-arginine-phenylethan) was previously shown to have
antibacterial properties. Here, we investigated the activity of this novel antimicrobial peptidomimetic on the yeast
Saccharomyces cerevisiae. We found that LTX109 was an efficient fungicide that killed all viable cells in an exponentially
growing population as well as a large proportion of cells in biofilm formed on an abiotic surface. LTX109 had similar killing
kinetics to the membrane-permeabilizing fungicide amphotericin B, which led us to investigate the ability of LTX109 to
disrupt plasma membrane integrity. S. cerevisiae cells exposed to a high concentration of LTX109 showed rapid release of
potassium and amino acids, suggesting that LTX109 acted by destabilizing the plasma membrane. This was supported by
the finding that cells were permeable to the fluorescent nucleic acid stain SYTOX Green after a few minutes of LTX109
treatment. We screened a haploid S. cerevisiae gene deletion library for mutants resistant to LTX109 to uncover potential
molecular targets. Eight genes conferred LTX109 resistance when deleted and six were involved in the sphingolipid
biosynthetic pathway (SUR1, SUR2, SKN1, IPT1, FEN1 and ORM2). The involvement of all of these genes in the biosynthetic
pathway for the fungal-specific lipids mannosylinositol phosphorylceramide (MIPC) and mannosyl di-(inositol phosphoryl)
ceramide (M(IP)2C) suggested that these lipids were essential for LTX109 sensitivity. Our observations are consistent with a
model in which LTX109 kills S. cerevisiae by nonspecific destabilization of the plasma membrane through direct or indirect
interaction with the sphingolipids.
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Introduction
Infections caused by pathogenic yeast such as Candida spp. affect
a large number of immunosuppressed patients and are an
increasing medical problem [1,2]. Fungal infections are currently
treated with one of four major classes of antifungals. Azoles target
ergosterol synthesis [3], polyenes bind to ergosterol in the cell
membrane and form pores [4,5], echinocandins inhibit cell wall
synthesis [6], and 5-fluorocytosine interferes with protein and
DNA synthesis [7].
Decreased susceptibility to the most frequently used antifungal,
fluconazole, has recently been reported, and the number of
nonsusceptible C. glabrata isolates from humans is increasing [8,9].
Resistance towards 5-fluorocystosine is also rapidly developing
[10]. Polyenes can be toxic [11] and echinocandins have a narrow
spectrum of activity [12]. An additional complication in the
treatment of nosocomial fungal infections is the frequent formation
by fungi of sessile communities called biofilms in association with
medical implants [13]. Limited nutrient access leads to slow-
growing, antibiotic tolerant cells in biofilms that can serve as a
reservoir for infection [14,15]. Most systemic antifungals are
fungistatic against yeasts, so they are primarily effective against
actively growing cells and have poor activity against cells in
biofilms.
The limited number of antifungal classes and drugs with
fungicidal properties raises the need for novel drugs with activity
against slow-growing and biofilm-forming pathogenic fungi
[16,17]. Antimicrobial peptides (AMPs) and modified forms of
AMPs offer an attractive alternative to conventional antifungal
drugs. AMPs are cationic and amphipathic peptides of 12–50
amino acids that are produced by species in almost every kingdom
and phylum of life [18]. The amphipathic structure of AMPs
suggests that they might have targets that are different from
conventional antifungals [19,20]. The high degradation rate of
many natural AMPs can be circumvented by backbone and side
chain alterations that create structural analogs that mimics natural
peptides [21]. A number of synthesized peptidomimetics have in
vitro antifungal activity, making these compounds attractive
candidates for novel antifungal drugs [22–24].
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We tested the antifungal activity of the short, antibacterial
peptidomimetic LTX109 (arginine-tertbutyl tryptophan-arginine-
phenylethan). LTX109 is based on an Arg-Trp-Arg sequence
found in the AMP bovine lactoferricin and was originally
developed as an antibacterial [25–27].
We used killing kinetics to describe the antimicrobial effect of
LTX109 and investigated its mode of action by measuring
transport of H+, K+, amino acids and a fluorescent dye across the
cell membrane. To uncover potential molecular targets that would
explain the fungicidal activity of LTX109, we screened a
Saccharomyces cerevisiae gene deletion library for mutants resistant
to LTX109. Most mutations that led to LTX109 resistance were
in genes involved in the synthesis of the sphingolipids mannosy-
linositol phosphorylceramide, MIPC, and mannosyl di-(inositol
phosphoryl) ceramide, M(IP)2C. These results indicate that
M(IP)2C and/or MIPC in the plasma membrane are essential
for the action of LTX109.
Materials and Methods
Strains, growth media and antifungal drugs
The S288c S. cerevisiae strain M3750 (MATa ura3-52) [28] was
used as the reference strain in all experiments unless otherwise
indicated, while the barcode-tagged deletion-mutant library was
from Johnston and coworkers [29]. S1278b (10560-2B; MATa
ura3-52 leu2:hisG his3:hisG) was used for biofilm susceptibility
experiments [30]. Complex YPD medium [31] was used in all
experiments except for amino acid release and biofilm where cells
were grown in synthetic complete medium [31]. LTX109 (Lytixar;
LytixBiopharmaAS, Oslo, Norway) and amphotericin B (Sigma)
were dissolved in water and stock solutions were kept at 220uC.
Broth microdilution minimal inhibitory concentrations
Minimal inhibitory concentration (MIC) values were measured
under static conditions in polystyrene microtiter plates. Two-fold
dilution series of antifungal drug were prepared in fresh YPD
medium and distributed to microtiter-plate wells. Overnight
cultures of wild type (WT) S288c were diluted and added to
antifungal-containing wells to a final concentration of 26105 cells/
ml. Growth inhibition was recorded with absorbance at 600 nm
after 24 hours at 30uC. The lowest drug concentration resulting in
90% growth inhibition was the MIC. MIC values of LTX109 were
determined three times with triplicate measurements, while MIC
values of amphotericin B was determined once with triplicate
measurements.
Killing kinetics
Overnight cultures of S. cerevisiae were diluted in fresh, preheated
YPD to 46105 cells/ml and incubated at 30uC with aeration.
Exponential growth phase cells were challenged with LTX109 or
amphotericin B at concentrations that were five times the MIC.
Control samples were treated with water to ensure that cells
applied in the time-kill experiment were in exponential growth
phase. Samples were taken at the indicated time points, diluted 10-
fold, and plated on YPD agar to determine colony forming units
(CFUs). The time-kill experiment was conducted in triplicates.
Acidification assay
Glucose-induced acidification was measured as previously
described [32] with modifications. Exponentially growing S.
cerevisiae cells were washed and resuspended in sterile water to a
final concentration of 108 cells/ml. Cells were subsequently
incubated with LTX109 (100 mg/ml) or water (control) for 10
minutes before the assay was initiated by addition of glucose to a
final concentration of 2% (w/v). The assay was conducted in
triplicate at room temperature with continuous magnetic stirring.
The assay was stopped by sampling at indicated time points,
followed by immediate centrifugation (20006g for two minutes).
pH of the resulting supernatants was measured and changes in
extracellular H+ concentration were calculated by applying the
obtained values to the equation pH=2log [H+].
Potassium release
Exponentially growing S. cerevisiae were harvested and resus-
pended in sterile water as described above. The potassium release
assay was initiated by addition of LTX109 to a final concentration
of 10 times the MIC. Samples treated with water instead of
LTX109 served as control. The assay was stopped by centrifuga-
tion of samples (13,0006g for 1 min) at indicated time points.
Supernatants were transferred to sterile microtubes for spectro-
metric analysis. Potassium concentrations were measured with a
FLM3 flame photometer (Radiometer). A standard concentration
curve was generated from diluted S3336 urine flame standard
(Radiometer). For spectrometric analysis, 5 ml of sample was
added to 1000 ml of S3336 lithium solution (Radiometer).
Experiments were carried out in triplicates at room temperature.
SYTOX Green uptake
SYTOX Green uptake was measured as previously described
[33] with modifications. Exponentially growing S. cerevisiae cells
were centrifuged, washed and suspended in 5 mM SYTOX Green
(Life Technologies) to a final concentration of 108 cells/ml.
LTX109 or water (control) was added to cell suspensions and
SYTOX Green uptake was recorded microscopically after 4, 8,
16, 32, 64 and 128 minutes. Fluorescence was recorded with a
Nikon Eclipse (Tokyo, Japan) fluorescence microscope equipped
with a F36–525 EGFP HC-filter set (AHF Analysentechnik).
Experiments were carried out at room temperature. SYTOX
green uptake upon LTX109 treatment was observed in three
independent experiments.
Amino acid release
Exponentially growing S. cerevisiae were harvested and suspend-
ed in sterile water or water with 10 times the MIC of LTX109 to a
final concentration of 26106 cells/ml. Loss of free amino acids
from cells was recorded at room temperature after 16 minutes
LTX109 exposure by instant centrifugation and subsequent
HPLC of the cell free supernatant. Amino acids were detected
and quantified by reverse-phase HPLC using an LKB-Alpha Plus
amino-acid analyzer and a mixture of L-a-amino acids, 1 nmol
each, as standards. The experiment was repeated three times.
Identification of LTX109-resistant mutants
Haploid knockout mutants of approximately 4000 nonessential
genes in the S288c deletion mutant library [29] were pooled.
About 106 cells from the mutant pool were transferred to YPD
agar containing 10 times the MIC of LTX109. After 72 hours at
30uC, 17 colonies were picked from the LTX109 plates. LTX109-
resistant clones were identified by PCR amplification and Sanger
sequencing of the unique barcode tag of each mutant. PCR
templates were DNA from clonal isolates of LTX109-resistant
mutants. Primers were 59-GATGTCCACGAGGTCTCT and 59-
CTGCAGCGAGGAGCCGTAAT. Gene deletions were identi-
fied using barcode sequences in the Stanford SGD deletion
database.
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Spot test
Exponentially growing S. cerevisiae cells were diluted to 107 cells/
ml and 6 ml of a 10-fold dilution series was spotted on YPD agar
and YPD agar containing 10 times the LTX109 MIC. Plates were
incubated for 24 hours at 30uC and growth results were recorded.
Biofilm susceptibility
S. cerevisiae (S1278b) cells were grown in Lab-TekTM Chamber
SlideTM System; PermanoxH (NUNC, Denmark) [34,35] in 1 ml
synthetic complete medium. Cells were initially allowed to form
biofilm for 12 hours before LTX109 was added for 5 hour in a
concentration of 0 or 70 mg/ml. The biofilm was subsequently
stained 15 minutes with Syto 9 (Invitrogen, Irvine, CA) for life cell
staining and propidium iodine for dead cell staining before
confocal laser scanning microscopy (CLSM). Imaging was carried
out using a 63x/0.95NA water immersion lens. CLSM was
performed with a Zeiss LSM510 microscope. Staining of biofilm
treated with LTX109 was repeated in four independent experi-
ments.
Results
Fungicidal properties of LTX109
We tested the antifungal properties of the peptidomimetic
LTX109 on the yeast S. cerevisiae using microdilution. LTX109 had
antifungal activity against S. cerevisiae at 26105 cells/ml with a
MIC value of 8 mg/ml compared to 2 mg/ml amphotericin B.
Assay to determine the killing kinetics of LTX109 against S.
cerevisiae revealed rapid and efficient fungicidal properties resulting
in a 3-log reduction in viable cells within one hour, while
amphotericin B required 90 minutes to achieve a similar fungicidal
effect when using drug concentrations in multiples of MIC (Fig. 1).
Additionally, LTX109 reduced the yeast population to the
detection limit within only 2 hours, an effect that was not achieved
by amphotericin B in the first 3 hours of exposure.
Exposure to LTX109 disrupts plasma membrane integrity
The speed with which LTX109 killed S. cerevisiae suggested that
the compound was acting directly on the plasma membrane. To
investigate the effect of LTX109 on plasma membrane integrity,
we measured H+ efflux, ion loss, loss of amino acids and uptake of
the fluorophore SYTOX Green across the plasma membrane.
Yeast cells treated with glucose acidify their surroundings
primarily by active transport of H+ by the plasma membrane H+-
ATPase [36]. We found that glucose-induced acidification was
completely absent when cells were treated with LTX109 for 10
minutes before glucose addition (Fig. 2A). These results suggested
that LTX109 decoupled the plasma membrane potential directly
or indirectly by inhibition of e.g. ATP synthesis.
We next tested the loss of potassium from cells treated with
LTX109. Potassium release occurred immediately and increased
during the first 16 minutes of exposure to LTX109, reaching a
steady state that was more than four times higher than the
maximum of the untreated control (Fig. 2B). Much of the K+ that
was lost was detected within the first two minutes of challenge with
a high LTX109 concentration. These results suggested that
LTX109 acted by direct interaction with and disturbance of the
plasma membrane rather than through indirect inhibition of
metabolism or another intracellular pathway.
To investigate if LTX109 treatment also led to loss of other
small molecules, cells were treated with LTX109 for 16 minutes
and free amino acids measured in the extract. Yeast cells treated
with LTX109 lost substantial amounts of at least 14 different
amino acids whereas cells treated with water only leaked aspartate
(Fig. 3). The loss corresponds well to the pool of intracellular
amino acids found in other experiments [37], suggesting that most
if not all free amino acids are depleted from cells treated with
LTX109.
We finally investigated if the membrane potential decoupling
was a consequence of plasma membrane destabilization by
monitoring the uptake of the 600-Dalton nucleic acid stain
SYTOX Green. SYTOX is an inorganic compound that
fluoresces upon DNA binding and SYTOX Green can only enter
a cell and fluoresce if the plasma membrane is compromised [38].
We found that untreated cells were impermeable to SYTOX
Green, while cells treated with LTX109 became permeable. The
dye was visible in the nucleus of LTX109-treated cells after only
eight minutes (Fig. 2C) and fluorescence increased with LTX109
exposure time.
Defects in sphingolipid synthesis lead to LTX109
resistance
To gain further insight into the LTX109 mode of action, we
screened a collection of haploid S. cerevisiae knockout mutants for
LTX109 resistance. We isolated 17 mutants that were resistant to
LTX109 at 10 times the MIC on YPD agar. Eight genes conferred
LTX109 resistance when deleted (Table 1; Fig. 4A). Six of the
identified genes (SUR1, FEN1, SUR2, IPT1, SKN1, ORM2) were
involved in the biosynthesis of sphingolipids, which are a major
plasma membrane component. Fen1p and Sur2p are involved in
synthesis of ceramides, which are precursors for inositol phospho-
ceramide (IPC), the first complex sphingolipid in the synthesis
pathway [39] (Fig 4B). Fen1p elongates long-chain fatty acids that
are linked to a sphingoid base to form ceramides [40] and Sur2p
hydroxylates dihydrosphingosine (DHS) to form phytosphingosine
(PHS) [41], which is the most abundant sphingoid base in yeast
ceramides [39]. Sur1p mannosylates IPC to form the intermediate
sphingolipid mannose inositol phosphoceramide (MIPC) [42] and
Skn1p and Ipt1p have similar functions in the biosynthesis of the
terminal sphingolipid mannosyl di-inositol phosphorylceramide
(M(IP)2C) [43]. Orm2p is a regulator of the sphingolipid
biosynthesis that links the biosynthesis to the regulatory Target
Of Rapamycin pathway [44]. Mutants that fail to activate Orm2p
have reduced levels of sphingolipids as do fen1, sur1, ipt1 and skn1
Figure 1. Fungicidal properties of LTX109 and amphotericin B.
Time-kill kinetics of exponentially growing yeast cells exposed to water
(circles) or five times the MIC of LTX109 (40 mg/ml) (squares) or
amphotericin B (10 mg/ml) (triangles). Viability was examined every half
hour as CFUs. Each data point is the average of three individual
measurements 6 standard deviation.
doi:10.1371/journal.pone.0069483.g001
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mutants [40,43,45,46], suggesting a role of sphinolipids in
sensitivity to LTX109.
One LTX109-resistant mutant was affected in the YSP2 gene,
which is involved in apoptosis, and another was affected in OPI9.
OPI9 has an unknown function but partly overlaps with VRP1,
which encodes an actin-associated protein with a role in actin
filament organization. The opi9 mutant therefore also has a partial
deletion of VRP1, so the LTX109-resistance phenotype could be
caused by loss of Vrp1p activity. Resistance of each mutant was
confirmed by spot-testing diluted yeast suspensions on YPD agar
containing LTX109 (Fig. 4A). Five of the mutants affected in
sphingolipid biosynthesis showed similar, high resistance towards
LTX109 (sur1, fen1, sur2, ipt1 and skn1).
LTX109 efficiently kill S. cerevisiae growing as biofilm
Because S288c is incompetent of biofilm growth [47,48] we
used the S1278b strain background to test the antifungal activity of
LTX109 against S. cerevisiae biofilm. To visualize the antifungal
properties of LTX109, we used CLSM in combination with Syto 9
DNA viability stain and propidium iodide that only penetrates
damaged cell membranes. Intermediate (12 h) S. cerevisiae biofilm
grown in batch culture slides were treated with 10 times MIC
LTX109 for 5 hours before LIVE/DEAD staining and CLSM
(Fig. 5). The LTX109 treatment killed the majority of the biofilm
population as indicated by uptake and staining of dead cells with
propidium iodide (Fig. 5), suggesting that LTX109 is also an
efficient anti-biofilm agent in addition to its fungicidal activity
against planktonic cells in exponential growth phase.
Discussion
This study demonstrated the fungicidal activity of the
peptidomimetic LTX109. Antimicrobial peptidomimetics are
peptide-like compounds, of which most are bactericides [49–53].
Figure 2. Transport of H+, K+ and a fluorescent dye by cells treated with LTX109. (A) Glucose-induced acidification of medium by yeast
cells. Exponentially growing S. cerevisiae was washed and suspended in sterile water and exposed to 100 mg/ml LTX109 (squares) or water (circles)
before glucose addition at time zero. Medium pH was measured and H+ concentration calculated from pH=2log [H+]. Each data point is the average
of three individual measurements with standard deviations as error bars. (B) Potassium release from yeast cells. Exponentially growing yeast cells
were washed, resuspended in water, and challenged with 100 mg/ml LTX109 (squares) or water (circles) at time zero. Potassium release was measured
using flame atomic absorption spectrometry in binary increasing intervals. Each data point is the average of three individual measurements 6
standard deviation. (C) Nomarski (left) and fluorescent (right) microscopy of SYTOX Green-stained yeast cells. Exponential growing cells were exposed
to 100 mg/ml LTX109 and SYTOX Green uptake was monitored. Cells treated with SYTOX Green and 0 mg/ml LTX109 served as control. SYTOX green
uptake upon LTX109 treatment was observed in three independent experiments.
doi:10.1371/journal.pone.0069483.g002
Figure 3. Efflux of amino acids from cells treated with LTX109.
Exponentially growing yeast cells were washed, resuspended in water,
and challenged with 70 mg/ml LTX109 (black bars) or water (grey bars)
for 16 minutes. Amino acids (one letter code) in the extracellular
medium were subsequently measured by HPLC. Each data point is the
average of three individual measurements 6 standard deviation.
doi:10.1371/journal.pone.0069483.g003
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LTX109 was previously shown to have bactericidal activity [27].
The arginine–tertbutyl tryptophan–arginine sequence of LTX109
makes it amphipathic, with two bulky side groups and two cationic
side groups that are proposed to interact with negatively charged
bacterial cell membranes [26].
We found similar killing kinetic for LTX109 and the membrane
permeabilizing drug amphotericin B, suggesting that the two
compounds could have a related mode of action. The rapid uptake
of the fluorescent dye SYTOX Green, potassium and amino acid
efflux from cells exposed to a high concentration of LTX109
suggest that this drug disturbs the plasma membrane by direct
interaction with one or several components in the plasma
membrane. Furthermore, inability of LTX109 treated cells to
acidify their surrounding media support an effect on the cell
membrane.
These results are similar to results with amphotericin B, which
also causes yeast cells to inhibit glucose-induced acidification [32]
and to release potassium as a consequence of general membrane
disorganization [54,55].
The high concentration of drug could have obscured other toxic
effects of LTX109 on S. cerevisiae, so we cannot exclude that
LTX109 has other effects in addition to membrane disruption as
previously discussed for peptide drugs [56].
To gain further insight into the mode of function of LTX109,
we screened for resistant mutants. Six of eight resistance mutants
were affected in sphingolipid biosynthesis, and five of these showed
similar, high resistance towards LTX109 (Fig. 4). fen1, sur1, ipt1
and skn1 mutants all have reduced amount of sphingolipids
[40,43,45,46] as do mutants that reduce Orm2p activity [44],
suggesting an essential role of complex sphingolipids in sensitivity
to LTX109. Lack of Sur2p lead to decreased sphinganine
hydroxylation, but does not prevent formation of MIPC [57].
Furthermore, the fen1 mutant produce reduced amount of
sphingolipids containing the C26 acyl group [40]. The resistance
phenotype of the sur2 and fen1 mutants therefore suggested that it
is not only the quantity, but also the structural modifications that
occur during sphingolipid synthesis that is required for optimal
LTX109 activity. The terminal steps of sphingolipid biosynthesis
in yeasts are MIPC and M(IP)2C. The fact that these lipids are
reduced in the resistant mutants suggests that MIPC and M(IP)2C
are essential for the fungicidal activity of LTX109, either by direct
interaction with LTX109 or by interaction with another mem-
Figure 4. Mutants in sphingolipid biosynthesis are resistant to
LTX109. (A) Spot test of wild type (WT) S. cerevisiae and eight deletion
mutants identified by screening a deletion collection for LTX109
resistance. Exponentially growing yeast was resuspended in YPD to 107
cells/ml and serially diluted 1:10. Aliquots (6 ml) were spotted on solid
YPD plates containing 70 mg/ml LTX109 (left panel), and without
LTX109 (right panel). (B) S. cerevisiae sphingolipid biosynthetic pathway.
doi:10.1371/journal.pone.0069483.g004
Table 1. S. cerevisiae genes that confer LTX109 resistance upon deletion.
Deleted gene and function ORF Gene product n
Sphingolipid biosynthesis
SUR1 YPL057C Mannosylinositol phosphorylceramide (MIPC) synthase catalytic subunit 2
SUR2 YDR297W Sphinganine C4-hydroxylase 8
ORM2 YLR350W Sphingolipid homeostasis. Interacts with serine palmitoyl transferase (SPT) 1
IPT1 YDR072C Inositolphosphotransferase, involved in synthesis of mannose-(inositol-P)2-ceramide (M(IP)2C) 1
FEN1 YCR034W Involved in membrane-bound fatty acid elongation up to 24 C (ceramide precursor) 1
SKN1 YGR143W Involved in the terminal M(IP)C RM(IP)2C process 2
Apoptosis
YSP2 YDR326C Mitochondrial protein in programmed cell death. 1
Unknown function
OPI9 YLR338W Dubious ORF unlikely to encode a protein. Partly overlaps VRP1 1
n, number of mutants identified.
doi:10.1371/journal.pone.0069483.t001
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brane components that is the target for LTX109. It does however
seem less likely that a component other than sphingolipids is the
target for LTX109 for two reasons, (i) mutants depleted of the
target would be expected to appear in the screen for mutants
resistant to LTX109. (ii) Alternatively, the target could depend on
sphingolipids for optimal activity, be essential for growth and thus
not appear in the screen, but then fen1, sur1, ipt1, skn1 and orm2
mutants would be expected to have reduced growth rates which
they do not (Fig. 4).
Sphingolipids are located primarily in the plasma membrane
[58] and are often clustered together with ergosterol in lipid rafts
[59]. Sphingolipids are not only a structural component of the cell
membrane, but serve vital functions in the heat-shock response,
cell cycle arrest, signaling pathways, endocytosis and protein
trafficking [60,61]. Fungal sphingolipids are highly similar to each
other [62,63], and the biosynthesis of complex fungal sphingolipids
is distinctly different from mammals [64]. This makes the fungal
sphingolipids attractive antifungal drug targets and several natural
compounds with anti-IPC synthase activity have been identified
[65–67].
The terminal M(IP)2C is the major sphingolipid in the fungal
plasma membrane [46] and has previously been suggested as a
target for the plant defensin Dahlia merckii antimicrobial peptide 1
(DmAMP1) [43,68,69]. DmAMP1 is a 50 amino acid amtimicro-
bial peptide that leads to nonselective passage of potassium,
calcium [70] and SYTOX Green [33]. Hence, DmAMP1 and
LTX109 could have similar modes of action, although DmAMP1
does not contain the Arg-Trp-Arg sequence that serves as basis for
LTX109.
Amphotericin B is currently the last in line treatment option for
severe fungal infections [71]. Alternative drug candidates might
therefore be developed for treatment in cases where use of
amphotericin B becomes limited due to resistance. Biofilm
formation on medical devices is a major nosocomial problem
and causes multidrug resistance [13]. Only a few of the current
systemic antifungals have activity against yeast biofilms [72,73],
but often it requires removal of the implant for effective treatment
[74]. Peptide antibiotics including LTX109 analogues have been
shown to be efficient drugs to kill bacterial biofilm cells [25,50].
This study shows for the first time a peptidomimetic with activity
against yeast biofilm. This observation suggests antifungal
peptidomimetics with rapid killing kinetics and membrane
permeabilizing activities are attractive drugs for yeast biofilm
treatment.
In conclusion, we have shown the efficient fungicidal properties
of a synthetic peptidomimetic, LTX109, that killed the yeast S.
cerevisiae with fast killing kinetics and complete eradication of viable
cells in exponential growth phase. We found that yeast cells treated
with a high concentration of LTX109 became permeable to free
amino acids, potassium and SYTOX Green and prevented proton
extrusion in response to a pulse of glucose. Fungal susceptibility to
LTX109 depended on biosynthesis of sphingolipids. The sphin-
golipids M(IP)2C and its precursor MIPC are found in fungal, but
not human membranes, making LTX109 and derivatives attrac-
tive drug candidates for fungal infection treatment as alternatives
to amphotericin B.
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